How The Prostate Cancer Market Will Look Over Next Decade

 
• By Kevin Grogan

As generic competition to J&J's Zytiga starts to line up ahead of possible launches in October, Datamonitor Healthcare has been weighing up the prostate cancer therapy space and seeing where the future competition will come from for Pfizer and Astellas' market leader Xtandi.

Consultation
The prostate cancer therapy market is set to keep growing • Source: Shutterstock

More from Anticancer

More from Therapy Areas